Research menu
Jump to menu

Publications:  Prof Aine McKnight

Treibel TA, Manisty C, Burton M, McKnight Á, Lambourne J, Augusto JB, Couto-Parada X, Cutino-Moguel T et al.(2020). COVID-19: PCR screening of asymptomatic health-care workers at London hospital. The Lancet vol. 395, (10237) 1608-1610.
Gibbons JM, Marno KM, Pike R, Lee WYJ, Jones CE, Ogunkolade BW, Pardieu C, Bryan A et al.(2020). HIV-1 accessory protein Vpr interacts with ReaF/RPRD2 to mitigate its antiviral activity. Journal of Virology vol. 94, (4)
Bourke NM, Napoletano S, Bannan C, Ahmed S, Bergin C, McKnight Á, Stevenson NJ(2018). Control of HIV infection by IFN-α: implications for latency and a cure. Cellular and Molecular Life Sciences vol. 75, (5) 775-783.
McCoy LE, McKnight Á(2017). Lessons learned from humoral responses of HIV patients. Curr Opin HIV AIDS vol. 12, (3) 195-202.
MCKNIGHT A(2017). RNA-Associated Early-Stage Antiviral Factor Is a Major Component of Lv2 Restriction. Journal of Virology
McCoy LE, McKnight Á(2017). Lessons learned from humoral responses of HIV patients. Curr Opin HIV AIDS
Jones CE, McKnight Á(2016). Retroviral restriction: Nature's own solution. Current Opinion in Infectious Diseases vol. 29, (6) 609-614.
Camprubi-Rimblas M, Peri F, McKnight A, Matteucci C, Guillamat-Prats R(2016). The EuroSciCon's 2015 Innate Immunity Summit. FUTURE VIROLOGY vol. 11, (10) 665-669.
Marno K, Al'Zoubi L, Pearson M, Posch M, McKnight Á, Wheeler AP(2015). The evolution of structured illumination microscopy in studies of HIV. Methods vol. 88, 20-27.
Deayton J, O'Sullivan E, McKnight A, Groves K, Bibby D, Clark D, Orkin C, Reeves I et al.(2015). Disease progression in HIV-1 controllers; uptake and outcome of antiretroviral therapy. HIV MEDICINE vol. 16, 20-20.
Dreja H, Pade C, Chen L, McKnight Á(2015). CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants. Journal of General Virology vol. 96, (7) 1899-1905.
Marno KM, Ogunkolade BW, Pade C, Oliveira NMM, O'Sullivan E, McKnight Á(2014). Novel restriction factor RNA-associated early-stage anti-viral factor (REAF) inhibits human and simian immunodeficiency viruses. Retrovirology vol. 11,
Alonso AG, Marno K, Ogunkolade W, Diaz-Delfin J, O'Sullivan E, McKnight A(2013). Human PAF1 inhibition of HIV-1. RETROVIROLOGY vol. 10, Article ARTN P39, S21-S22.
Marno K, Ogunkolade B, Pade C, Oliveira N, O'Sullivan E, McKnight A(2013). Novel restriction factor RNA-associated early-stage anti-viral factor (REAF) inhibits human and simian immunodefi ciency viruses. RETROVIROLOGY vol. 10, Article ARTN P57, S26-S26.
McKnight A(2013). The ins and outs of HIV restriction. RETROVIROLOGY vol. 10, Article ARTN O30, S6-S6.
Groves KC, Bibby DF, Clark DA, Isaksen A, Deayton JR, Anderson J, Orkin C, Stagg AJ et al.(2012). Disease Progression in HIV-1-Infected Viremic Controllers. J Acquir Immune Defic Syndr vol. 61, (4) 407-416.
Tang J, Wang L, Markiv A, Jeffs SA, Dreja H, McKnight A, He M, Kang AS(2012). Accessing of recombinant human monoclonal antibodies from patient libraries by eukaryotic ribosome display. Human Antibodies vol. 21, (1-2) 1-11.
Liu L, Oliveira NMM, Cheney KM, Pade C, Dreja H, Bergin A-MH, Borgdorff V, Beach DH et al.(2011). A whole genome screen for HIV restriction factors. Retrovirology vol. 8,
Harrison IP, McKnight A(2011). Cellular entry via an actin and clathrin-dependent route is required for Lv2 restriction of HIV-2. Virology vol. 415, (1) 47-55.
Dreja H, O'Sullivan E, Pade C, Greene KM, Gao H, Aubin K, Hand J, Isaksen A et al.(2010). Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. J Gen Virol vol. 91, (Pt 11) 2794-2803.
Oliveira NMM, Trikha R, McKnight Á(2010). A novel envelope mediated post entry restriction of murine leukaemia virus in human cells is Ref1/TRIM5α independent. Retrovirology vol. 7,
Groves K, Bibby D, Clark D, Isaksen A, Deayton J, Anderson J, Orkin C, Stagg AJ et al. (2010). Disease Progression Despite Suppressed Plasma Viral Load in Human Immunodeficiency Infected Viremic Controllers. AIDS RESEARCH AND HUMAN RETROVIRUSES. vol. 26, A163-A163.
Aasa-Chapman M, Hue S, Cheney KM, Forsman A, McKnight A (2010). Tier 1-like neutralization sensitive HIV-1 viruses develop in vivo despite the development and onslaught of potent neutralizing antibodies. AIDS RESEARCH AND HUMAN RETROVIRUSES. vol. 26, A158-A158.
Koh WWL, Forsman A, Hué S, van der Velden GJ, Yirrell DL, McKnight A, Weiss RA, Aasa-Chapman MMI(2010). Novel subtype C human immunodeficiency virus type 1 envelopes cloned directly from plasma: coreceptor usage and neutralization phenotypes. J Gen Virol vol. 91, (Pt 9) 2374-2380.
Richards KH, Aasa-Chapman MMI, McKnight A, Clapham PR(2010). Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies. RETROVIROLOGY vol. 7, Article 48,
Deayton J, Bibby D, Orkin C, O'Sullivan E, McKnight A, Clark D (2010). Inter-clade dual HIV-1 infection in the UK - an emerging phenomenon.
Kelly BA, Harrison I, McKnight A, Dobson CB(2010). Anti-infective activity of apolipoprotein domain derived peptides in vitro: identification of novel antimicrobial peptides related to apolipoprotein B with anti-HIV activity. BMC IMMUNOL vol. 11, Article 13,
Corti D, Langedijk JPM, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D et al.(2010). Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals. PLOS ONE vol. 5, (1) Article e8805,
Cheney KM, McKnight A(2010). Interferon-Alpha Mediates Restriction of Human Immunodeficiency Virus Type-1 Replication in Primary Human Macrophages at an Early Stage of Replication. PLoS One vol. 5, (10)
Doyle T, Garcia-Diaz A, Booth C, Dreja H, McKnight A, Johnson M, Geretti AM(2009). High-risk sexual behaviour and HIV-1 superinfection: an indication for early initiation of antiretroviral therapy?. HIV MED vol. 10, 54-55.
Groves KC, Bibby D, Isaksen A, Deayton J, Anderson J, Orkin C, Stagg AJ, McKnight A(2009). Altered T cell homeostasis and activation in HIV-1 elite suppressors with low CD4+T-cell counts. RETROVIROLOGY vol. 6, Article P250,
Dibben O, Assa-Chapman M, Lewis J, McKnight A, Williams I, Borrow P(2009). Investigation of the sensitivity of acute-phase HIV-1 isolates to type I interferons. RETROVIROLOGY vol. 6, Article P4,
Dreja H, O'Sullivan E, Pade C, Aubin K, Isaksen A, D'Souza C, Hand J, Orkin C et al.(2009). Neutralisation activity in a geographically diverse East London cohort of HIV-1 infected patients. RETROVIROLOGY vol. 6, Article P63,
Forsman A, Beirnaert E, Aasa-Chapman MMI, Hoorelbeke B, Hijazi K, Koh W, Tack V, Szynol A et al.(2008). Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol vol. 82, (24) 12069-12081.
Corti D, Pinna D, Vanzetta F, Balla S, Dreja H, O'Sullivan E, Pade C, Hinz A et al. (2008). A Panel of HIV-1 Neutralizing Antibodies Isolated from Non-clade B HIV-1 Infected Donors. AIDS RESEARCH AND HUMAN RETROVIRUSES. vol. 24, 3-3.
Weiss RA, Willey S, Aasa-Chapman M, McKnight A (2008). Role of Complement in HIV Infection: A 2-edged Sword?. AIDS RESEARCH AND HUMAN RETROVIRUSES. vol. 24, 84-84.
McKnight A, Aasa-Chapman MMI(2007). Clade specific neutralising vaccines for HIV: an appropriate target?. Curr HIV Res vol. 5, (6) 554-560.
Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB(2007). Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity. FEBS J vol. 274, (17) 4511-4525.
Aasa-Chapman MMI, Seymour CR, Williams I, McKnight A(2006). Novel envelope determinants for CCR3 use by human immunodeficiency virus. J Virol vol. 80, (21) 10884-10889.
Aasa-Chapman MMI, Aubin K, Williams I, McKnight A(2006). Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species. Virology vol. 351, (2) 489-496.
Marchant D, Neil SJD, McKnight A(2006). Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. J Gen Virol vol. 87, (Pt 2) 411-418.
Marchant D, Neil SJD, Aubin K, Schmitz C, McKnight A(2005). An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction. J Virol vol. 79, (15) 9410-9418.
Neil SJD, Aasa-Chapman MMI, Clapham PR, Nibbs RJ, McKnight A, Weiss RA(2005). The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes. J Virol vol. 79, (15) 9618-9624.
Neil SJD, McKnight A, Gustafsson K, Weiss RA(2005). HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation. Blood vol. 105, (12) 4693-4699.
Aasa-Chapman MMI, Holuigue S, Aubin K, Wong M, Jones NA, Cornforth D, Pellegrino P, Newton P et al.(2005). Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol vol. 79, (5) 2823-2830.
Aasa-Chapman MMI, Hayman A, Newton P, Cornforth D, Williams I, Borrow P, Balfe P, McKnight A(2004). Development of the antibody response in acute HIV-1 infection. AIDS vol. 18, (3) 371-381.
Schmitz C, Marchant D, Neil SJD, Aubin K, Reuter S, Dittmar MT, McKnight A(2004). Lv2, a novel postentry restriction, is mediated by both capsid and envelope. J Virol vol. 78, (4) 2006-2016.
McKnight A, Weiss RA(2003). Blocking the docking of HIV-1. Proc Natl Acad Sci U S A vol. 100, (19) 10581-10582.
Morner A, Thomas JA, Bjorling E, Munson PJ, Lucas SB, McKnight A(2003). Productive HIV-2 infection in the brain is restricted to macrophages/microglia. AIDS vol. 17, (10) 1451-1455.
Willey SJ, Reeves JD, Hudson R, Miyake K, Dejucq N, Schols D, De Clercq E, Bell J et al.(2003). Identification of a subset of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus strains able to exploit an alternative coreceptor on untransformed human brain and lymphoid cells. J VIROL vol. 77, (11) 6138-6152.
Thomas ER, Shotton C, Weiss RA, Clapham PR, McKnight A(2003). CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS vol. 17, (3) 291-300.
Willey S, Roulet V, Reeves JD, Kergadallan M-L, Thomas E, McKnight A, Jégou B, Dejucq-Rainsford N(2003). Human Leydig cells are productively infected by some HIV-2 and SIV strains but not by HIV-1. AIDS vol. 17, (2) 183-188.
Clapham PR, McKnight A(2002). Cell surface receptors, virus entry and tropism of primate lentiviruses. J GEN VIROL vol. 83, 1809-1829.
McKnight A, Griffiths DJ, Dittmar M, Clapham P, Thomas E(2001). Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2. J Virol vol. 75, (15) 6914-6922.
Clapham PR, McKnight A(2001). HIV-1 receptors and cell tropism. BRIT MED BULL vol. 58, 43-59.
Return to top